In vivo studies reveled that apigenin treatment reduced tumor growth and a significant decrease in HDAC activity that correlated with increased levels of p21/waf1and Bax protein along with a reduction in protein levels of bcl2 that favored apoptosis in tumor cells of the mice (Pandey et al., 2012). This evidence concerns the gene BCL2 and neoplasm.